Viking Therapeutics

Compare

6,989 Followers

VKTX Stock Chart & Stats

$34.93

$0.22(0.67%)

At close: Jan 21 4:00 PM EST

$34.93

$0.22(0.67%)

Day’s Range― - ―

52-Week Range$18.92 - $79.10

Previous CloseN/A

Volume7.75M

Average Volume (3M)5.12M

Market Cap

$3.95B

Enterprise Value$2.24B

Total Cash (Recent Filing)$100.38M

Total Debt (Recent Filing)$755.00K

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Feb 11, 2026

EPS Estimate

-0.89

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.81

Shares Outstanding113,036,350

10 Day Avg. Volume4,434,308

30 Day Avg. Volume5,120,459

Financial Highlights & Ratios

PEG Ratio-3.63

Price to Book (P/B)4.98

Price to Sales (P/S)0.00

P/FCF Ratio-49.98

Enterprise Value/Market Cap0.57

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-19.98K

Enterprise Value/Ebitda-8.15

Forecast

1Y Price Target

$95.40

Price Target Upside173.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

Bulls Say, Bears Say

Bulls Say

Clinical TrialsVK2735 subQ is a GLP-1/GIP dual agonist and is currently enrolling patients in two Phase III trials.

Market OpportunityViking poised to take advantage of growing obesity market with efficacy and optionality; initiating at BUY.

Regulatory ProgressManagement plans to meet with the FDA to discuss next steps for oral VK2735, indicating progress in regulatory discussions.

Bears Say

Adverse Event RatesThere may be much higher reporting rates for GI adverse events than before, potentially driving higher adverse event rates, including in the placebo group.

Adverse EventsShares were down 42% following the news of high rates of gastrointestinal-related adverse events and discontinuations from therapy in the Phase 2 VENTURE trial.

Viking Therapeutics News

Midday Fly By: Nvidia hits $5T market cap, Boeing takes big 777X charge

The major averages were broadly higher again, adding to this week’s sharp gains as optimism around artificial intelligence...

16h ago

Skyworks upgraded, UnitedHealth downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

19h ago

3 Best Stocks to Buy Now, 10/29/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

21h ago

BTBT

RELY

Canaccord starts Viking Therapeutics with Buy on obesity potential

Canaccord analyst Edward Nash initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $106 price target...

23h ago

VKTX

Viking Therapeutics initiated with a Buy at Canaccord

Canaccord initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $106 price target Published first on...

23h ago

VKTX

Viking Therapeutics price target lowered to $75 from $80 at JPMorgan

JPMorgan lowered the firm’s price target on Viking Therapeutics (VKTX) to $75 from $80 and keeps an Overweight...

6d ago

VKTX

Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Viking Therapeutics (VKTX) to $102 from $98 and keeps an...

7d ago

VKTX

Viking Therapeutics offered ‘transformative’ Q3 update, says Cantor Fitzgerald

Cantor Fitzgerald tells investors after Viking Therapeutics (VKTX)’ “transformative” Q3 update that “this was the most bullish update...

7d ago

VKTX

Viking Therapeutics reports Q3 EPS (81c), consensus (67c)

At September 30, Viking held cash, cash equivalents and short-term investments of $715M vs. $903M as of December...

7d ago

VKTX

Viking Therapeutics options imply 7.6% move in share price post-earnings

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 9:4. Implied volatility suggests the...

8d ago

VKTX

Options Volatility and Implied Earnings Moves Today, October 22, 2025

Today, several major companies are expected to report earnings: Annaly Capital (NLY), AT&T (T), International Business Machines (IBM),...

8d ago

Viking Therapeutics initiates VK2735 maintenance dosing clinical trial

Viking Therapeutics (VKTX) initiated an exploratory maintenance dosing study of VK2735, the company’s dual agonist of the glucagon-like...

9d ago

VKTX

Options Volatility and Implied Earnings Moves This Week, October 20 – October 24, 2025

This week, several major companies will be reporting earnings. Among them are Tesla (TSLA), Intel (INTC), Netflix (NFLX),...

10d ago

Viking Therapeutics’ VK2735: A Promising Phase 3 Study for Weight Management

Viking Therapeutics (($VKTX)) announced an update on their ongoing clinical study. Study Overview: Viking Therapeutics is conducting a...

2d ago

VKTX

VKTX FAQ

What was Viking Therapeutics’s price range in the past 12 months?

Viking Therapeutics lowest stock price was $18.92 and its highest was $79.10 in the past 12 months.

What is Viking Therapeutics’s market cap?

Viking Therapeutics’s market cap is $3.95B.

When is Viking Therapeutics’s upcoming earnings report date?

Viking Therapeutics’s upcoming earnings report date is Feb 11, 2026 which is in 104 days.

How were Viking Therapeutics’s earnings last quarter?

Viking Therapeutics released its earnings results on Oct 22, 2025. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.1.

Is Viking Therapeutics overvalued?

According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viking Therapeutics pay dividends?

Viking Therapeutics does not currently pay dividends.

What is Viking Therapeutics’s EPS estimate?

Viking Therapeutics’s EPS estimate is -0.89.

How many shares outstanding does Viking Therapeutics have?

Viking Therapeutics has 113,036,350 shares outstanding.

What happened to Viking Therapeutics’s price movement after its last earnings report?

Viking Therapeutics reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went up 7.957%.

Which hedge fund is a major shareholder of Viking Therapeutics?

Currently, no hedge funds are holding shares in VKTX

Viking Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.23%

Trailing 12-Months

Asset Growth

-21.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics (VKTX) Earnings & Revenues

Historic Earnings Reports

VKTX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in clinical trials for obesity treatments, with positive Phase II results and the initiation of Phase III trials. However, the financial report showed increased losses and decreased cash reserves.View all VKTX earnings summaries

VKTX Stock 12 Month Forecast

Average Price Target

$95.40

▲(173.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","48":"$48","74":"$74","100":"$100","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,48,74,100,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.37,34.88,42.39,49.900000000000006,57.41,64.92,72.43,79.94,87.45,94.96000000000001,102.47,109.98,117.49000000000001,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.37,32.60307692307693,37.83615384615385,43.06923076923077,48.30230769230769,53.535384615384615,58.76846153846154,64.00153846153846,69.23461538461538,74.4676923076923,79.70076923076923,84.93384615384615,90.16692307692308,{"y":95.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.37,27.495384615384616,27.62076923076923,27.746153846153845,27.871538461538464,27.99692307692308,28.122307692307693,28.247692307692308,28.373076923076923,28.498461538461537,28.623846153846156,28.74923076923077,28.874615384615385,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >